New Frontiers in the Management of Ovarian Cancer: Exploring the Role of PARP Inhibitors in the Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 15, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Clovis Oncology

Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five-year survival rate is only 45%. Recently, more options in managing patients with ovarian cancer have emerged. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. It is important for healthcare professionals to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.

Upon completion of this activity, participants will be able to:

  • Explore safety and efficacy outcomes from recent clinical data on PARP inhibitors, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy

  • Analyze factors that impact treatment decision-making throughout the course of advanced ovarian cancer

  • Examine the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition, including those with BRCA-mutated disease

  • Identify strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer

  • Assess the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into the current ovarian cancer management paradigm

Faculty: Shannon N. Westin MD, MPH
Associate Professor
Director, Early Drug Development
Dept. of Gynecologic Oncology and Reproductive Medicine
UT MD Anderson Cancer Center


Dr. Westin serves as a consultant for AstraZeneca, Clovis, Genentech, Medivation, Merck, Ovation, Pfizer, and Takeda. She has received grant/research support from AstraZeneca, Bayer, Clovis, Cotinga, Genentech, and Tesaro. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Clovis Oncology

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue